# Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

> **NCT00161668** · — · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 500 (—)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Mylotarg

## Key facts

- **NCT ID:** NCT00161668
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 500 (—)
- **Last updated:** 2007-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00161668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00161668, "Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00161668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*